Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have been given an average rating of "Buy" by the fourteen research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $87.15.
A number of equities research analysts have weighed in on the company. Morgan Stanley reduced their target price on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Truist Financial reaffirmed a "buy" rating and set a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. HC Wainwright reaffirmed a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research note on Wednesday, June 25th. The Goldman Sachs Group initiated coverage on Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price objective on the stock. Finally, Cantor Fitzgerald upgraded Viking Therapeutics to a "strong-buy" rating in a report on Tuesday, April 29th.
View Our Latest Analysis on Viking Therapeutics
Hedge Funds Weigh In On Viking Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in VKTX. Quarry LP boosted its holdings in Viking Therapeutics by 1,621.4% in the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 1,135 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Viking Therapeutics by 64.8% in the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 536 shares in the last quarter. FIL Ltd grew its position in Viking Therapeutics by 116.8% in the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 648 shares during the period. NBC Securities Inc. increased its stake in Viking Therapeutics by 222,100.0% during the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,221 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in Viking Therapeutics by 170.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 851 shares in the last quarter. Institutional investors own 76.03% of the company's stock.
Viking Therapeutics Stock Up 3.9%
Shares of NASDAQ VKTX traded up $1.05 during midday trading on Tuesday, reaching $27.72. The company's stock had a trading volume of 4,095,205 shares, compared to its average volume of 4,026,892. The business's 50 day moving average price is $27.27 and its two-hundred day moving average price is $30.04. Viking Therapeutics has a fifty-two week low of $18.92 and a fifty-two week high of $81.73.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same period in the prior year, the company posted ($0.26) earnings per share. The company's revenue was up .0% compared to the same quarter last year. On average, equities research analysts expect that Viking Therapeutics will post -1.56 earnings per share for the current fiscal year.
Viking Therapeutics Company Profile
(
Get Free ReportViking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
